Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Definitely one of the better worded RNS we have received lately. I like the way it CLEARLY states
“ Use of the Financing Facility in no way affects the Company's current agreement with GlobalCo, which is still in the process of assessing whether to exercise an option to exploit the CDX antibody on a worldwide basis”
Let it roll....
SP likes it !!
On 13 January 2021, the Company announced that it had successfully completed the development of its CDX antibody with GlobalCo and, as a result of its successful collaboration with GlobalCo, the Company had chosen a clone of its CDX antibody that is ready for IND application-enabling studies.
On 13 January 2021, the Company announced that it had successfully completed the development of its CDX antibody with GlobalCo and, as a result of its successful collaboration with GlobalCo, the Company had chosen a clone of its CDX antibody that is ready for IND application-enabling studies.
Peter Redmond
Peter Redmond is a corporate financier with some 30 years’ experience in corporate finance and venture capital. He has acted on and assisted a wide range of companies to attain a listing over many years, on the Unlisted Securities Market, the Full List and AIM, whether by IPO or in many cases via reversals, across a wide range of sectors, ranging from technology through financial services to natural resources and biotech, in recent years often as a director and shareholder of the companies concerned. He has been active over many years in corporate rescues and reconstructions on AIM and in reverse transactions into a range of investing companies. He was a founder director of Cleeve Capital plc (now Satellite Solutions plc) and Mithril Capital plc (now BeHeard plc), both of which were admitted to the Standard List of the London Stock Exchange, and took a leading role in the reconstruction and refinancing of AIM-quoted Kennedy Investments and 3Legs Resources plc. He is a director of AIM-quoted Pires Investments plc.
These are the people who i have faith in, people who have devoted their lives to medical science and cooperate financing and are now devoted to Hemogenyx, these are people at the top of the field with world wide respect and acclamation, these are people who have been there and done it and have decided that the CNL is the best pathway forward to create wealth for the company.
Sir Marc Fieldman
Professor Sir Marc Feldmann is a pre-eminent medically trained immunologist at the University of Oxford where he was Head of the Kennedy Institute of Rheumatology until 2014 and now Emeritus Professor. He trained in medicine at Melbourne University and then earned a Ph.D. in Immunology at the Walter & Eliza Hall Institute with Sir Gus Nossal, before working in London at the Imperial Cancer Research Fund. Sir Feldmann’s main research interests are immunoregulation, understanding mechanisms of autoimmunity and the role of cytokines in disease, and working out how to fill unmet medical needs.
His work in London led to the generation of a new hypothesis for the mechanism of autoimmunity, linking upregulated antigen presentation and cytokine expression. Testing this hypothesis led to the discovery, with colleague Sir Ravinder Maini, of the pivotal role of TNFa (Tumor Necrosis Factor alpha) in the pathogenesis of rheumatoid arthritis. This major discovery has therapy not only of rheumatoid arthritis but other chronic inflammatory diseases (eg Inflammatory bowel disease, psoriasis, ankylosing spondylitis), and helped change the perception of monoclonal antibodies from niche products to mainstream therapeutics. Anti-TNF therapeutics are the current leading drug class with 2016 sales exceeding $36 Billion.
This has led to much scientific recognition, for example election to the Royal Society and Academy of Medical Sciences in London, the National Academy of Sciences USA and the Australian Academy of Science, and multiple major International prizes: including the Crafoord Prize of the Royal Swedish Academy of Sciences, the Albert Lasker Clinical Research Award (NY), the Ernst Schering Prize , the Paul Janssen Award for Biomedical Research and the Canada-Gairdner Award. He was also the first recipient in biology or medicine of the EU/ European Patent Inventor of the Year Award in the Lifetime Achievement category. In addition, Sir Marc has advised more than 20 of the largest pharmaceutical and biotech companies in the world and has mentored some of the most successful scientists, many of whom have become senior figures in the commercial pharmaceutical world. Sir Marc was knighted in the 2010 Queen’s Birthday and was in Australia with the knighthood equivalent, the Companion of the Order of Australia.
I would advise anyone who hasn’t taken the time to read through the prospectus to do so, clearly lays out the road map for the future, all extremely positive, anyone who thinks Mint would hand over 60million to company with c.40m MC with any thoughts that they may not see it again needs to pause for a minute and think clearly.
For me the company is now in the best shape of its life with access to such funds.
On and up,
Good luck all
There really is a raft of news on the Horizon from so many different front, if I wasn’t fully loaded with this and others stocks of me filling my boots right now at these prices, knee jerk reactions are always the best entry points in my opinion
offer or for the admission to trading on a regulated market
The Directors, having considered various strategies for financing the Group, have concluded that the issuance of the Convertible Loan Notes to Mint Capital is the most favourable option for the Company to accelerate and broaden its development pipeline of novel therapies and treatment for blood cancers and viral diseases.
This prospectus is being published to allow Admission of the New Ordinary Shares on conversion of the Convertible Loan Notes.
Use and estimated net amount of the proceeds
On the basis that the Company will, in due course, draw down the Facility in full, the Company intends to use the proceeds of the issue of the Convertible Loan Notes to accelerate the development and marketability of its product candidates as follows: (i) the Company intends to use approximately £20 million of the proceeds to achieve clinical proof of concept for the Company’s CDX bi-specific antibody product candidate if and when needed; (ii) the Company intends to use approximately £6 million of the proceeds to achieve clinical proof of concept for HEMO-CAR-T; (iii) the Company intends to use approximately £12 million of the proceeds to achieve preclinical and clinical proof of concept for CBR; and (iv) the Company intends to use the remaining £22 million of the proceeds for future projects and development stages and general working capital purposes, as well as to pay the fees and expenses associated with the entry into the Facility, the General Meeting and the publication and approval of this document.
What’s your target price ?
Good luck
Morning Target,
It was at the same time that this interview came out, I think it was money munch which posted another report not specifically naming EVG but was along similar lines as huw spoke and a few here were wondering if there was a connection. I thought I saved it but can’t find it now.
If I remember correctly I think maybe you also posted another version of the same report after money munch - ring any bells ?
*link it to
Munch,
Do you still have the report you posted a few weeks back at the time Huw first spoke about this new treatment. I can’t remember much else about it other than we were trying to it and Huws comments together?
Vague I know, lol
As a result of the Company's successful collaboration with GlobalCo, the Company has chosen a clone of its CDX antibody that is ready for investigational new drug ("IND") application-enabling studies, a significant step toward clinical trials.
This is great news and is exactly as Vlad promised in the previous update on CDX with regards to timescales and route options etc , I think deal should be signed in coming weeks. As others have mentioned this is only one piece of news on the horizon we have on several fronts.
Hopefully sub 10p will now be a thing past.
Very well done Vlad and team